Context Therapeutics Inc. (CNTX): Price and Financial Metrics
CNTX Price/Volume Stats
| Current price | $1.41 | 52-week high | $1.69 |
| Prev. close | $1.39 | 52-week low | $0.47 |
| Day low | $1.37 | Volume | 45,900 |
| Day high | $1.50 | Avg. volume | 53,663 |
| 50-day MA | $1.21 | Dividend yield | N/A |
| 200-day MA | $1.13 | Market Cap | 22.52M |
CNTX Stock Price Chart Interactive Chart >
Context Therapeutics Inc. (CNTX) Company Bio
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.
Latest CNTX News From Around the Web
Below are the latest news stories about CONTEXT THERAPEUTICS INC that investors may wish to consider to help them evaluate CNTX as an investment opportunity.
Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsCTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent |
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented at SITC 38th Annual Meeting on November 3rd PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumor |
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An AnalysisNEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning! |
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingPHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA. Details of the presenta |
CNTX Price Returns
| 1-mo | 28.18% |
| 3-mo | 25.89% |
| 6-mo | 24.78% |
| 1-year | 107.38% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 24.78% |
| 2023 | 73.39% |
| 2022 | -75.50% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...